Journal
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 327, Issue 18, Pages 1806-1811Publisher
AMER MEDICAL ASSOC
DOI: 10.1001/jama.2022.5692
Keywords
-
Categories
Ask authors/readers for more resources
The US Preventive Services Task Force has updated its recommendation on screening for COPD in asymptomatic adults, stating that it has no net benefit.
IMPORTANCE Chronic obstructive pulmonary disease (COPD) is an irreversible reduction of airflow in the lungs. Progression to severe disease can prevent participation in normal activities because of deterioration of lung function. In 2020 it was estimated that approximately 6% of US adults had been diagnosed with COPD. Chronic lower respiratory disease, composed mainly of COPD, is the sixth leading cause of death in the US. OBJECTIVE To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a reaffirmation evidence update that focused on targeted key questions for benefits and harms of screening for COPD in asymptomatic adults and treatment in screen-detected or screen-relevant adults. POPULATION Asymptomatic adults who do not recognize or report respiratory symptoms. EVIDENCE ASSESSMENT Using a reaffirmation process, the USPSTF concludes with moderate certainty that screening for COPD in asymptomatic adults has no net benefit. RECOMMENDATION The USPSTF recommends against screening for COPD in asymptomatic adults. (D recommendation)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available